key: cord-0047900-ls8k8npd
authors: Coz Yataco, Angel O.; Simpson, Steven Q.
title: COVID-19 Sepsis - A Nudge Toward Antibiotic Stewardship
date: 2020-07-21
journal: Chest
DOI: 10.1016/j.chest.2020.07.023
sha: e129c59d52ac782b52cf4b5c408257eaaa8bea44
doc_id: 47900
cord_uid: ls8k8npd

nan

Sepsis is life-threatening organ dysfunction caused by a dysregulated host response to infection; such infections can be caused by bacteria, fungi, or in the case of COVID-19, a virus (SARS-CoV-2). In bacterial sepsis, the most common variety, early and appropriate antibiotics are crucial to decrease mortality and the progression to more severe forms of disease. 1 Severe COVID-19 is frequently characterized by multiorgan failure including hypotension and shock, acute respiratory failure, acute kidney injury (AKI), coagulation abnormalities, and others.

Both bacterial sepsis and COVID-19 lead to similar patterns of multiorgan failure. Since SARS-CoV-2 is an infecting organism, it is logical to conclude that severe COVID-19 is indeed sepsis caused by SARS-CoV-2.

When bacteria are the causative organism most patients improve with oral antimicrobials, and only a few develop sepsis or more severe forms that require aggressive inpatient care. In the case of COVID-19, some patients are asymptomatic, others develop mild symptoms, and only a small fraction progress to severe COVID-19. A key difference between viral sepsis and either bacterial or fungal sepsis is that for most viral infections, specific therapies are substantially less effective than antibacterial or antifungal agents. Specific to the current pandemic, remdesivir shortens duration of illness for survivors, but does not improve survival. We believe this inability to exogenously alter the infectious burden results in the necessity for care that is principally supportive. It potentially explains the high mortality rate of patients with severe COVID-19 who required invasive mechanical ventilation (MV) in early reports, a lethality higher than expected for severe ARDS related to sepsis of another cause.

COVID-19 can be said to be sepsis with no highly effective antimicrobial therapy.

Although we are unlikely to ever see a trial comparing antibiotics vs. no antibiotics in bacterial sepsis, Kumar et al. 2 provided the closest evidence to that scenario. The mortality rate of septic shock patients who received inappropriate antimicrobials bordered 90%, while those receiving appropriate antibiotics had a fivefold mortality reduction. The mortality of the inappropriate antibiotic group is similar in magnitude to the 88% mortality reported in severe COVID-19 patients on MV. The COVID-19 patients could not receive appropriate antimicrobials because such therapy for SARS-CoV-2 did not exist.

No currently active physician has practiced in an era without antibiotics to treat bacterial infections, but the circumstance we describe brings to mind reports from that era. Before the advent of penicillin, pneumococcal pneumonia conferred an 84% mortality in patients ≥ 70; bacteremic pneumonia in that age group was uniformly fatal. 3 Antibiotics were not the only medical treatment lacking, as ICUs, MV, and the ability to assess for VTE or DIC were nonexistent. However, it is highly likely that without antibiotics, these other technologies could only be partially effective. infections. For instance, in 2019 there were 200,000 cases and over 9,000 deaths caused by extended-spectrum β-lactamase (ESBL) organisms; these numbers reflect a 50% increase compared with comparable estimates in 2013. In addition, the need to treat ESBL infections with carbapenems is likely to raise the rates of resistance to this antibiotic class over time. 5 The emergence of Candida auris, a highly resistant fungus, represents a threat for patients in ICUs.

This pathogen was isolated in over 300 patients in 2019, a significant and worrisome growth in incidence that has tripled in the few years since it was first reported in the US in 2013. This organism has demonstrated resistance to all antimicrobial classes used to treat fungal infections, and it is associated with a very high mortality rate.

We consider COVID-19 a reminder that reinforces the need for and the practice of antibiotic stewardship by physicians and health systems. Without effective antibiotics, most sepsis care becomes purely supportive. There is, however, a good side to understanding that we are dealing with viral sepsis and subsequent ARDS, which is that supportive care is more effective than it was in the pre-antibiotic era. Intensivists understand more principles of early recognition, MV, renal replacement therapy, nutrition and VTE prophylaxis. With time and application of best practices, survival of critically ill COVID-19 patients is improving.

Regarding antimicrobial resistance, infection control efforts are demonstrably effective, which should promote compliance with these initiatives by ICU clinicians. Over time, the rates of carbapenem-resistant Acinetobacter baumannii, multi-drug resistant Pseudomonas aeruginosa, methicillin-resistant Staphylococcus aureus and Vancomycin-resistant Enterococcus have all declined. 4, 5 The rates of C. difficile infection, a marker of indiscriminate use of antibiotics, are also declining. These are all reasons to strengthen resolve and to continue to apply the best evidence-based treatments for both COVID-19 and for antimicrobial resistant organisms.

COVID-19 is sepsis caused by SARS-CoV-2, a virus for which there is little in the way of antimicrobial therapy. Because it is sepsis, known tenets of sepsis care and organ support must be our guiding principles. Surprisingly, a key lesson that we must take from the war on this viral sepsis is that we must redouble our efforts to be stewards of antimicrobials and ensure that we have adequate means to control bacterial and fungal infection. Moreover, it is critical that high priority is given to RCTs testing drugs to treat SARS-CoV-2 and the ensuing sepsis. As we face subsequent waves of this plague, patients will do better if we are both able and prepared to provide more than just supportive care.

Increased Time to Initial Antimicrobial Administration Is Associated With Progression to Septic Shock in Severe Sepsis Patients

Initiation of inappropriate antimicrobial therapy results in a fivefold reduction of survival in human septic shock

Clinical Significance of Bacteremia in Pneumococcic Pneumonia

Key Takeaways From the U.S. CDC's 2019 Antibiotic Resistance Threats Report for Frontline Providers

Centers for Disease Control and Prevention-Antibiotic Resistance Threats in the United States